Related Experiment Video
Updated: Aug 19, 2025
10:03
Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
1.9K
Challenges with Cell-based Therapies for Type 1 Diabetes Mellitus.
Prakriti Siwakoti1,2, Claire Rennie1, Yanan Huang2,3
1School of Life Sciences, Faculty of Science, University of Technology Sydney, 2007, Ultimo, NSW, Australia.
Stem Cell Reviews and Reports
|November 26, 2022
Summary
Type 1 diabetes (T1D) treatment faces challenges with current insulin therapy. Emerging cell-based therapies and bioengineered devices show promise for beta cell replacement and a potential cure for T1D.
Area of Science:
- Endocrinology
- Regenerative Medicine
- Biotechnology
Background:
- Type 1 diabetes (T1D) is an autoimmune disease causing pancreatic beta cell destruction and glucose dysregulation.
- Current T1D management relies on exogenous insulin, requiring lifelong monitoring and injections.
- Beta cell replacement therapies offer a potential cure but face significant hurdles.
Purpose of the Study:
- To review the benefits and limitations of cell-based therapies for T1D beta cell replacement.
- To explore the application of bioengineered devices and nanotechnology in enhancing islet transplantation.
- To discuss emerging strategies for overcoming challenges in T1D curative treatments.
Main Methods:
- Literature review of current and emerging T1D treatment strategies.
- Analysis of cell-based therapies, including stem cell-derived beta cells.
- Evaluation of bioengineered devices and nanotechnology in islet transplantation.
Main Results:
- Cell-based therapies face limitations like donor tissue scarcity, cell viability, and transplant longevity.
- Bioengineered devices and nanotechnology offer potential solutions to improve transplantation efficacy and reduce immunosuppression.
- Stem cell-derived beta cells and advanced delivery systems are key areas of investigation.
Conclusions:
- Cell-based therapies and bioengineered approaches hold significant promise for a T1D cure.
- Overcoming challenges in cell production, transplantation, and immune rejection is crucial for clinical translation.
- Further research and development are needed to realize the full potential of these advanced T1D treatments.
More Related Videos
16:26Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
5.9K
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
8.0K
Related Concept Videos
01:22Diabetes Mellitus: Overview and Type I Subtype
2.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.9K
01:22Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
01:15Diabetes: Management and Pharmacotherapy
328
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
328
01:20Pathophysiology of Diabetes
1.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.1K
01:16Insulin: Dosing Regimen and Adverse Effects
226
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
226
01:22iPS Cell Differentiation
2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K